Skip to content
PoliTrackerPrototype - alpha version 0.1
← Policies

Proposed

Bill · 119th Congress · S 5265

USTRx Act

Refreshed 1 h ago

Introduced 2026-08-05Topic: health care · economy jobs

Summary

Summary by the Congressional Research Service

Use Sovereignty To reduce Rx Act or the USTRx Act This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the Office of the U.S. Trade Representative (USTR). The negotiator must conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers. The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States. The bill also requires the USTR to submit to Congress a plan to respond to certain adverse acts, policies, or practices of high-income countries that are related to the trade of pharmaceutical products.

Full text and official record on Congress.gov

Sponsors

Action history

DateChamberActionStatus effect
2026-08-05SenateRead twice and referred to the Committee on Finance.refer
2026-08-05Introduced in Senateintroduce
Source: GovInfo Bill Status (Library of Congress), fetched 2026-09-18. Provisions and opinion polling arrive in a later release.